Pranjal Gambhir Joins Lazard as Head of Medical Technology
Pranjal Gambhir Joins Lazard as Head of Medical Technology
PR Newswire
NEW YORK, Sept. 28, 2026
NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Lazard, Inc. (NYSE: LAZ) announced today that Pranjal Gambhir joined the firm as Head of Medical Technology, based in New York.
In this role, Pranjal will lead coverage of Medical Technology companies, advising clients on strategy and corporate development transactions across the sector.
"Pranjal has broad and deep experience across the Medical Technology sector, and his arrival deepens the coverage we can offer clients," said David Gluckman, Global Head of Healthcare at Lazard. "His background across multiple sub-sectors gives our Healthcare Group added strategic depth as we continue to grow our practice."
Pranjal joins Lazard from Citi, where he was most recently Managing Director covering Medical Technology companies across multiple sub-sectors. He spent 20 years at Citi across various roles in New York and New Delhi.
"The Medical Technology sector continues to evolve rapidly, creating both opportunity and complexity for clients," said Pranjal Gambhir. "Lazard's independent perspective and global platform are exactly what leadership teams, boards and investors need, and I look forward to helping them navigate what's ahead. "
Pranjal earned his MBA from the Indian School of Business and Bachelor of Commerce from Delhi University.
Founded in 1848, Lazard is the preeminent financial advisory and asset management firm, with operations in North and South America, Europe, the Middle East, Asia, and Australia. Lazard provides advice on mergers and acquisitions, capital markets and capital solutions, restructuring and liability management, geopolitics, and other strategic matters, as well as asset management and investment solutions to institutions, corporations, governments, partnerships, family offices, and high net worth individuals. Lazard is listed on the New York Stock Exchange as Lazard, Inc. under the ticker LAZ. For more information, please visit Lazard.com and follow Lazard on LinkedIn.
Media Relations
Jessica Francisco
+1 212-632-6571
jessica.francisco@lazard.com
Shannon Houston
+1 212-632-6880
shannon.houston@lazard.com
Investor Relations
William Murdock
+1 212-632-1564
william.murdock@lazard.com
SOURCE Lazard
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States